| abstract |
The present invention provides an aqueous suspension type pharmaceutical formulation that inhibits premature dissolution and absorption even when administered orally, has a relatively low risk of onset of unexpected side effects caused by a temporary increase in blood concentration, and Contains (1)‑(4). (1)(3aR,4S,7R,7aS)-2-{(1R,2R)-2-[4-(1,2-benzisothiazol-3-yl)piperazine-1-ylmethyl] Cyclohexylmethyl}hexahydro-4,7-methylene-2H-isoindole-1,3-dione, its pharmaceutically acceptable acid addition salt, or a mixture of these; (2) yellow (3) a dispersant; and (4) water. |